4D Molecular Therapeutics, Inc 10-K for FY2023
4D Molecular Therapeutics, Inc. (FDMT)
10-K
2024-02-29
For: 2023-12-31
View Original
Added on
April 08, 2026
About this 10-K
4D Molecular Therapeutics, Inc filed this 10-K on February 29, 2024, covering the fiscal year ended December 31, 2023 (FY2023).
Headline figures
Fiscal year ended December 31, 2023, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $20.72M
- up 562.3% from $3.13M a year earlier
- Net loss
- $100.84M
- compared with a net loss of $107.49M a year earlier
- Diluted EPS
- -$2.58
- compared with -$3.32 a year earlier